Genetically engineered cell factories produce glycoengineered vaccines that target antigen presenting cells and reduce antigen specific T-cell reactivity

Publication date: Available online 17 August 2018

Source: Journal of Allergy and Clinical Immunology

Author(s): Caroline B.K. Mathiesen, Michael C. Carlsson, Stephanie Brand, Svenning Rune Möller, Manja Idorn, Per T. Straten, Anders E. Pedersen, Sally Dabelsteen, Adnan Halim, Peter Adler Würtzen, Jens Brimnes, Henrik Ipsen, Bent L. Petersen, Hans H. Wandall

https://ift.tt/2Bkg9MB